Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Clinical and Experimental Metastasis

• Publication date

  2011-09-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s10585-011-9421-9PMID 21953073PMCID PMC7416514
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Brain metastases as preventive and therapeutic targets

  2011cited by this paper
• A Mitotic Phosphorylation Feedback Network Connects Cdk1, Plk1, 53BP1, and Chk2 to Inactivate the G2/M DNA Damage Checkpoint

  2010cited by this paper
• Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy

  2010cited by this paper
• Polo-like kinase 1 as predictive marker and therapeutic target for radiotherapy in rectal cancer.

  2010cited by this paper
• Targeting Polo-like Kinase in Cancer Therapy

  2010cited by this paper
• Sensitivity of Cancer Cells to Plk1 Inhibitor GSK461364A Is Associated with Loss of p53 Function and Chromosome Instability

  2010cited by this paper
• Heterogeneous Blood–Tumor Barrier Permeability Determines Drug Efficacy in Experimental Brain Metastases of Breast Cancer

  2010cited by this paper
• Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics

  2010cited by this paper
• Plk1-mediated Phosphorylation of Topors Regulates p53 Stability*

  2009cited by this paper
• Latent bone metastasis in breast cancer tied to Src-dependent survival signals.

  2009cited by this paper
• A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53

  2009cited by this paper
• Phase I first-in-human study of the polo-like kinase-1 selective inhibitor, GSK461364, in patients with advanced solid tumors.

  2009cited by this paper
• Vorinostat Inhibits Brain Metastatic Colonization in a Model of Triple-Negative Breast Cancer and Induces DNA Double-Strand Breaks

  2009cited by this paper
• Polo‐like kinase‐1 phosphorylates MDM2 at Ser260 and stimulates MDM2‐mediated p53 turnover

  2009cited by this paper
• Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.

  2009cited by this paper
• Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21WAF1/CIP1

  2009cited by this paper
• TP53 Status and Response to Chemotherapy in Breast Cancer

  2008cited by this paper
• Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization

  2008cited by this paper
• Heterogeneity of Breast Cancer Metastases: Comparison of Therapeutic Target Expression and Promoter Methylation Between Primary Tumors and Their Multifocal Metastases

  2008cited by this paper
• p73-mediated transcriptional activity is negatively regulated by Polo-like kinase 1

  2008cited by this paper
• Inhibitory Role of Plk1 in the Regulation of p73-dependent Apoptosis through Physical Interaction and Phosphorylation*

  2008cited by this paper
• The Blood-Brain Barrier and Cancer: Transporters, Treatment, and Trojan Horses

  2007cited by this paper
• Mitotic drug targets and the development of novel anti-mitotic anticancer drugs.

  2007cited by this paper
• Polo-like kinase 1 is involved in invasion through extracellular matrix.

  2007cited by this paper
• Tumor metastasis: mechanistic insights and clinical challenges

  2006cited by this paper
• The Consensus Coding Sequences of Human Breast and Colorectal Cancers

  2006cited by this paper
• Topors acts as a SUMO‐1 E3 ligase for p53 in vitro and in vivo

  2005cited by this paper
• Polo-like kinase isoforms in breast cancer: expression patterns and prognostic implications

  2005cited by this paper
• Breast cancer metastasis to the central nervous system.

  2005cited by this paper
• Polo-like kinases and the orchestration of cell division

  2004cited by this paper
• Cancer inhibition in nude mice after systemic application of U6 promoter-driven short hairpin RNAs against PLK1.

  2004cited by this paper
• Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53*

  2004cited by this paper
• Phosphorylation of BRCA2 by the Polo-like kinase Plk1 is regulated by DNA damage and mitotic progression

  2004cited by this paper
• Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

  2003cited by this paper
• Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells

  2002cited by this paper
• Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells.

  2002cited by this paper
• Expression of polo‐like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease

  2002cited by this paper
• High incidence of central nervous system involvement in patients with metastatic or locally advanced breast cancer treated with epirubicin and docetaxel.

  2001cited by this paper
• A Bone‐Seeking Clone Exhibits Different Biological Properties from the MDA‐MB‐231 Parental Human Breast Cancer Cells and a Brain‐Seeking Clone In Vivo and In Vitro

  2001cited by this paper
• MDM2--master regulator of the p53 tumor suppressor protein.

  2000cited by this paper
• Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function.

  2000cited by this paper
• Polo-like kinase: a novel marker of proliferation: correlation with estrogen-receptor expression in human breast cancer.

  2000cited by this paper
• Loss of heterozygosity accumulation in primary breast carcinomas and additionally in corresponding distant metastases is associated with poor outcome.

  1999cited by this paper
• Accumulation of Genetic Alterations in Brain Metastases of Sporadic Breast Carcinomas Is Associated with Reduced Survival after Metastasis

  1999cited by this paper
• Central nervous system progression of metastatic breast cancer in patients treated with paclitaxel

  1995cited by this paper
• Response of brain metastases from breast cancer to systemic chemotherapy

  1992cited by this paper

• Biomarkers of Alzheimer’s Disease Associated with Programmed Cell Death Reveal Four Repurposed Drugs

  2024cites this paper
• Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling

  2023cites this paper
• CEBP-β and PLK1 as Potential Mediators of the Breast Cancer/Obesity Crosstalk: In Vitro and In Silico Analyses

  2023cites this paper
• Pan-cancer and single-cell analysis reveals FAM83D expression as a cancer prognostic biomarker

  2022cites this paper
• Preclinical Models of Brain Metastases in Breast Cancer

  2022cites this paper
• Brain Metastasis Cell Lines Panel: A Public Resource of Organotropic Cell Lines

  2020cites this paper
• Brain metastasis models: What should we aim to achieve better treatments?

  2020cites this paper
• Polo-like kinase 1 is involved in apoptosis, invasion, and metastasis of pancreatic ductal adenocarcinoma

  2020cites this paper
• A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt's lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis.

  2020cites this paper
• Supplementary Table 1. Recent research publications using passive targeting technology(s) in targeting brain metastases of breast cancer

  2019cites this paper
• Innovations in Metastatic Brain Tumor Treatment

  2019cites this paper
• Targeting forkhead box M1 transcription factor in breast cancer

  2018cites this paper
• Brain Metastasis as Complication of Systemic Cancers

  2018cites this paper
• Essential Role of Polo-like Kinase 1 (Plk1) Oncogene in Tumor Growth and Metastasis of Tamoxifen-Resistant Breast Cancer

  2018cites this paper
• Combination of PI3K/Akt Pathway Inhibition and Plk1 Depletion Can Enhance Chemosensitivity to Gemcitabine in Pancreatic Carcinoma

  2018cites this paper
• Blood‐brain barrier‐penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer

  2017cites this paper
• The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis

  2017cites this paper
• PLK1 Inhibition: Prospective Role for the Treatment of Pediatric Tumors.

  2016cites this paper
• Bio-Inspired and Nanotechnology-Enabled Drug Delivery for Diabetes and Brain Cancer

  2016cites this paper
• Polo-like kinase 1 as a prognostic and therapeutic target in high-grade brain tumors

  2015cites this paper
• Chapter 9 – New Targeted Therapies for Brain Metastases from Breast and Lung Cancer and Melanoma

  2015cites this paper
• Emerging strategies for treating brain metastases from breast cancer.

  2015cites this paper
• Value of Oncogenes for the Prediction of Brain Metastases at Initial Diagnosis: A Review of Published Data

  2014influential citation
• Chemotherapy and biological treatment options in breast cancer patients with brain metastasis: an update

  2014cites this paper
• [Brain metastases epidemiology and biology].

  2013cites this paper
• Breast cancer brain metastases: new directions in systemic therapy

  2013cites this paper
• CNS Metastases in Breast Cancer: Old Challenge, New Frontiers

  2013cites this paper
• In vitro targeting of Polo-like kinase 1 in bladder carcinoma

  2013cites this paper
• Inhibition of polo-like kinase 1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitisation.

  2013cites this paper
• Curative Effects of Thiacremonone against Acetaminophen-Induced Acute Hepatic Failure via Inhibition of Proinflammatory Cytokines Production and Infiltration of Cytotoxic Immune Cells and Kupffer Cells

  2013cites this paper
• A novel animal model of human breast cancer metastasis to the spine: a pilot study using intracardiac injection and luciferase-expressing cells.

  2013cites this paper
• Editorial: spine metastasis.

  2013cites this paper
• Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of both cancer and endothelial cells.

  2013cites this paper
• Biology in prevention and treatment of brain metastases

  2013cites this paper
• Biology of brain metastases and novel targeted therapies: time to translate the research.

  2013cites this paper
• Identification of potent virtual leads to design novel PLK1 inhibitors: pharmacophore modelling, virtual screening and molecular docking studies

  2013cites this paper
• Impact of anti-PLK 1 siRNA-containing F 3-targeted liposomes on the viability of both cancer and endothelial cells

  2013cites this paper
• Breast cancer metastasis: issues for the personalization of its prevention and treatment.

  2013cites this paper
• In Silico Discovery of Mitosis Regulation Networks Associated with Early Distant Metastases in Estrogen Receptor Positive Breast Cancers

  2013cites this paper
• Factors Important to Personalizing Therapy for Preventing and Treating Metastatic Disease Semipersonalized Medicine

  2013cites this paper
• Inhibition of PLK1 in glioblastoma multiforme induces mitotic catastrophe and enhances radiosensitization

  2013cites this paper
• TPI-287, a New Taxane Family Member, Reduces the Brain Metastatic Colonization of Breast Cancer Cells

  2012cites this paper
• The Effects of Polo-like Kinase 4 on Cancer Cell Motility

  2012cites this paper
• Brain metastases: pathobiology and emerging targeted therapies

  2012cites this paper
• Targeted therapy in brain metastasis

  2012cites this paper
• Combining stereotactic radiosurgery and systemic therapy for brain metastases: a potential role for temozolomide

  2012cites this paper
• Preclinical Development TPI-287 , a New Taxane Family Member , Reduces the Brain Metastatic Colonization of Breast Cancer Cells

  2012cites this paper
• PLK1: A Promising Therapeutic Target for Prostate Cancer Treatment

  year unknowncites this paper